A Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
Latest Information Update: 11 Dec 2024
Price :
$35 *
At a glance
- Drugs PRGN-3007 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Advanced breast cancer; B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Haematological malignancies; Mantle-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man
- 09 Dec 2024 Planned End Date changed from 1 Jan 2026 to 1 Mar 2026.
- 09 Dec 2024 Planned primary completion date changed from 1 Jan 2026 to 1 Mar 2025.
- 06 Dec 2024 Status changed from recruiting to active, no longer recruiting.